RxDoctor Payments Data

John Carter, MD

Family Medicine · Hobart, INNPI 1851326086

Payments from drug & device makers

$7,156in general payments, 2019–2025

Across 437 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$608
  • Novo Nordisk$444
  • Lilly USA, LLC$418
  • Pfizer$388
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$378
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,156 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$86,281
Medicare patients
272
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$155,355
OzempicSemaglutide62$107,971
EliquisApixaban37$50,542
JanuviaSitagliptin Phosphate28$40,463
FarxigaDapagliflozin Propanediol23$38,450
XifaxanRifaximin11$35,366
MounjaroTirzepatide22$33,591
XareltoRivaroxaban24$30,136
RexultiBrexpiprazole16$26,730
TrulicityDulaglutide16$22,867
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$20,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,702
Breo ElliptaFluticasone/Vilanterol18$11,232
Tresiba Flextouch U-100Insulin Degludec16$9,508
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$338$155,355103 claims
Novo NordiskOzempic$444$107,97162 claims
Lilly USA, LLCMounjaro, Trulicity$418$56,45838 claims
PfizerEliquis$388$50,54237 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$257$50,04351 claims
AstraZenecaFarxiga, Symbicort$608$41,88934 claims
MerckJanuvia$224$40,46328 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$378$35,36611 claims
Johnson & JohnsonXarelto$109$30,13624 claims
Otsuka America Pharmaceutical, Inc.Rexulti$280$26,73016 claims
AbbVieSynthroid$1,247$2,53743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →